Neoplasia, cancer and late effects

Comparison of HbA1c and oral glucose tolerance testing for the diagnosis of patients with and at risk of diabetes among long-term bone marrow transplant survivors

ea0034p171 | Neoplasia, cancer and late effects

Neuroendocrine biomarkers change with treatment in small cell lung cancer

ea0034p172 | Neoplasia, cancer and late effects

Late presentation predicts endocrine dysfunction in patients with Langerhans cell histiocytosis: a retrospective analysis of the West of Scotland LCH service 1998–2012

ea0034p173 | Neoplasia, cancer and late effects

The first reported mutations in the pituitary tumor-transforming gene binding factor

ea0034p174 | Neoplasia, cancer and late effects

Bromodomain inhibitors reduce proliferation and increase apoptosis of human neuroendocrine tumour cells

ea0034p175 | Neoplasia, cancer and late effects

Adrenocortical cancer: rare but gloomy cause of adrenal lesions

ea0034p176 | Neoplasia, cancer and late effects

Metastatic paraganglioma with unknown genetics: to screen or not to screen the family?

ea0034p177 | Neoplasia, cancer and late effects

Clinical dilemmas in diagnosing pheochromocytoma

ea0034p178 | Neoplasia, cancer and late effects

Inhibition of radioiodine uptake by PBF in breast cells is consistent with sodium–iodide symporter repression in the thyroid

ea0034p179 | Neoplasia, cancer and late effects

Expression modulation of tumour necrosis factor α and tumour necrosis factor receptor 1 genes in breast cancer cell lines (MCF-7) by some selected indigenous cytotoxic plants

ea0034p180 | Neoplasia, cancer and late effects

Characteristics of ‘foregut’ carcinoid tumours occurring in multiple endocrine neoplasia type 1

ea0034p181 | Neoplasia, cancer and late effects

Inherited mutations in the SDH complex increase metastatic malignant potential of paragnglioma and phaeochromocytoma tumours

ea0034p182 | Neoplasia, cancer and late effects

Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation

ea0034p183 | Neoplasia, cancer and late effects

Long-term negative effects in young cancer survivors: metabolic disorders in the patients after complex treatment for brain tumors and acute lymphoblastic leukemia in childhood and adolescence

ea0034p184 | Neoplasia, cancer and late effects

Diagnosis of adrenocortical carcinoma; urinary steroid profiles measured by GC:MS

ea0034p185 | Neoplasia, cancer and late effects

A rare adrenal lieomyosarcome in a subject with lupus and the antiphospholipid syndrome

ea0034p186 | Neoplasia, cancer and late effects

RET genetic screening in patients with multiple endocrine neoplasia type 2 and medullary thyroid carcinoma: experience of the Exeter Molecular Genetics Laboratory

ea0034p187 | Neoplasia, cancer and late effects

MIBG-avidity in genetically distinct phaeochromocytoma and paraganglioma populations

ea0034p188 | Neoplasia, cancer and late effects

SDHB surveillance regime: a single UK institution experience

ea0034p189 | Neoplasia, cancer and late effects

Multiple endocrine neoplasia type 2A in a large family with a C620G mutation of the RET proto-oncogene: diagnostic, treatment, and ethical challenges

ea0034p190 | Neoplasia, cancer and late effects

An incidental diagnosis…

ea0034p191 | Neoplasia, cancer and late effects

Endocrine Abstracts

Society for Endocrinology BES 2014

Poster Presentations

Calycosin suppresses breast cancer cell growth via ERβ-mediated inhibition of IGF1R pathway

A challenging case of hypokalaemic Cushing's crisis

Investigating neuroendocrine markers of small cell lung cancer

Comparison of HbA1c and oral glucose tolerance testing for the diagnosis of patients with and at risk of diabetes among long-term bone marrow transplant survivors

Neuroendocrine biomarkers change with treatment in small cell lung cancer

Late presentation predicts endocrine dysfunction in patients with Langerhans cell histiocytosis: a retrospective analysis of the West of Scotland LCH service 1998–2012

The first reported mutations in the pituitary tumor-transforming gene binding factor

Bromodomain inhibitors reduce proliferation and increase apoptosis of human neuroendocrine tumour cells

Adrenocortical cancer: rare but gloomy cause of adrenal lesions

Metastatic paraganglioma with unknown genetics: to screen or not to screen the family?

Clinical dilemmas in diagnosing pheochromocytoma

Inhibition of radioiodine uptake by PBF in breast cells is consistent with sodium–iodide symporter repression in the thyroid

Expression modulation of tumour necrosis factor α and tumour necrosis factor receptor 1 genes in breast cancer cell lines (MCF-7) by some selected indigenous cytotoxic plants

Characteristics of ‘foregut’ carcinoid tumours occurring in multiple endocrine neoplasia type 1

Inherited mutations in the SDH complex increase metastatic malignant potential of paragnglioma and phaeochromocytoma tumours

Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation

Long-term negative effects in young cancer survivors: metabolic disorders in the patients after complex treatment for brain tumors and acute lymphoblastic leukemia in childhood and adolescence

Diagnosis of adrenocortical carcinoma; urinary steroid profiles measured by GC:MS

A rare adrenal lieomyosarcome in a subject with lupus and the antiphospholipid syndrome

RET genetic screening in patients with multiple endocrine neoplasia type 2 and medullary thyroid carcinoma: experience of the Exeter Molecular Genetics Laboratory

MIBG-avidity in genetically distinct phaeochromocytoma and paraganglioma populations

SDHB surveillance regime: a single UK institution experience

Multiple endocrine neoplasia type 2A in a large family with a C620G mutation of the RET proto-oncogene: diagnostic, treatment, and ethical challenges

An incidental diagnosis…

ATR kinase function is modulated by the proto-oncogene PBF

BiosciAbstracts